TDC
NVLN

Thompson Davis & Co’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Thompson Davis & Co’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,430
Closed -$26K – 1237
2017
Q1 		$26K Buy
+2,430
New +$24.8K 0.04% 413

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Thompson Davis & Co's NVLN Position: Q2 2017 in Review

Thompson Davis & Co sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2017, closing a stake of 2,430 shares — an estimated $26K sold.

Thompson Davis & Co first reported a position in NVLN in Q1 2017 and held it in 1 quarter. The position peaked at $26K in Q1 2017. 76 funds tracked by Wall St. Rank hold NVLN as of Q2 2017.

  • Thompson Davis & Co reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 2,430 Novelion Therapeutics Inc. Common Shares shares in Q2 2017, an estimated $26K.
  • Thompson Davis & Co first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Novelion Therapeutics Inc. Common Shares position peaked at $26K in Q1 2017.
  • 76 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.